Literature DB >> 6611397

Kinetics of 11C-labeled opiates in the brain of rhesus monkeys.

P Hartvig, K Bergström, B Lindberg, P O Lundberg, H Lundqvist, B Långström, H Svärd, A Rane.   

Abstract

The regional uptake in the brain of Rhesus monkeys of i.v. administered 11C-labeled morphine, codeine, heroin and pethidine was studied by means of positron emission tomography. The technique measures the sum of parent drug and radiolabeled metabolites. (For the sake of simplicity the drug derived radioactivity is denoted by the drug name.) Morphine had a limited uptake to discrete areas of the brain. The maximum normalized uptake, with respect to dose per kilogram body weight, was about 0.2, i.e., 20% of the calculated activity if the drug had been evenly distributed throughout the body of the monkey. Maximum radioactivity appeared 30 to 45 min after injection. Morphine left the brain slowly with an estimated half-life of more than 2 hr. An area with a normalized uptake of about 1.0 was detected centrally in the lowest horizontal transsection of the skull. The origin of this area was identified as the pituitary. Codeine, heroin and pethidine were taken up to the brain to a larger extent than morphine, with maximum normalized uptakes of 2.6, 4.6 and 6.3, respectively. Maximum radioactivities of these drugs were achieved earlier and the elimination rates were faster than for morphine. Differences in the uptake of these drugs to the brain, as well as differences in time to maximal normalized uptake and rate of disappearance are considered to reflect differences in the lipophilic character between the drugs. Pethidine had the most rapid and extensive uptake followed by heroin, codeine and morphine in order of decreasing lipophilicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611397

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Pharmacokinetic optimisation of opioid treatment in acute pain therapy.

Authors:  R N Upton; T J Semple; P E Macintyre
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 2.  Non-invasive methods to study drug disposition: positron emission tomography. Detection and quantification of brain receptors in man.

Authors:  B Sadzot; G Franck
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 3.  Modeling of PET data in CNS drug discovery and development.

Authors:  Katarina Varnäs; Andrea Varrone; Lars Farde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-05-10       Impact factor: 2.745

4.  Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET).

Authors:  P Hartvig; S A Eckernäs; L Lindström; B Ekblom; U Bondesson; H Lundqvist; C Halldin; K Någren; B Långström
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey.

Authors:  David A White; Stephen G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  2003-03-18       Impact factor: 4.530

6.  Randomised double blind trial of morphine versus diamorphine for sedation of preterm neonates.

Authors:  C M Wood; J A Rushforth; R Hartley; H Dean; J Wild; M I Levene
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

Review 7.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

8.  Pain and opiate receptors: considerations for the design of positron emission tomography studies.

Authors:  B Sadzot; J J Frost
Journal:  Anesth Prog       Date:  1990 Mar-Jun

Review 9.  A Survey of Molecular Imaging of Opioid Receptors.

Authors:  Paul Cumming; János Marton; Tuomas O Lilius; Dag Erlend Olberg; Axel Rominger
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.